Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients

The Breast ◽  
2013 ◽  
Vol 22 (5) ◽  
pp. 926-932 ◽  
Author(s):  
G. Sanna ◽  
M. Pestrin ◽  
E. Zafarana ◽  
C. Biagioni ◽  
D. Cavaciocchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Breast Cancer Patients ◽  
Dose Dense

scholarly journals HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

2012 ◽  
Vol 10 (1) ◽  
Author(s):  
George Fountzilas ◽  
Christos Valavanis ◽  
Vassiliki Kotoula ◽  
Anastasia G Eleftheraki ◽  
Konstantine T Kalogeras ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Breast Cancer Patients ◽  
Sequential Chemotherapy ◽  
Dose Dense

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment

2018 ◽  
Vol 171 (3) ◽  
pp. 571-580 ◽  
Author(s):  
Emanuel C. A. Bauer ◽  
◽  
Fabienne Schochter ◽  
Peter Widschwendter ◽  
Amelie DeGregorio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Breast Cancer Patients

scholarly journals MO11-7 The decision of adjuvant treatment using OncotypeDX and outcome in early breast cancer patients

2021 ◽  
Vol 32 ◽  
pp. S304
Author(s):  
Yuri Ozaki ◽  
Masataka Sawaki ◽  
Masaya Hattori ◽  
Akiyo Yoshimura ◽  
Haruru Kotani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document